Kelly Doyle, PhD

Associate Professor of Pathology (Clinical), University of Utah School of Medicine

Education

• Doctorate Degree—Medicinal Chemistry, University of Utah
• Fellowship—Clinical Chemistry, University of Utah School of Medicine
• Fellowship—Oncological Sciences, University of Utah, Huntsman Cancer Institute

Certification/Affiliations

• American Board of Clinical Chemistry
• American Association of Clinical Chemistry Academy

Research Interests

• Clinical application and implementation of mass spectrometry
• Emerging biomarkers
• Toxicology
• Endocrinology
• Laboratory best practices

Recent Publications

• Kushnir MM, et al. Clinical utility and analytical aspects of direct measurements of free hormones using mass spectrometry-based methods. J App Lab Med. 2022; jfac010. Published online ahead of print.
• Nelson HA, et al. Mitigation of biotin interference in manual and automated immunoassays by pre-conjugating biotinylated antibodies to the streptavidin surface as an alternative to biotin depletion. J Appl Lab Med. 2022;7(3):762–75.
• Doyle K, et al. Verifying clinically derived reference intervals for daily excretion rates of fractionated metanephrines using modern indirect reference interval models. Am J Clin Pathol. 2020;156(4):691–99.
• Kroner GM, et al. Cannabinol (CBN) cross-reacts with two urine immunoassays designed to detect tetrahydrocannabinol (THC) metabolite. J Appl Lab Med. 2020;5(3):569–74.
• Johnson-Davis KL, et al. Therapeutic drug monitoring in pregnant patients. Ther Drug Monit. 2020;42(2):172–80.
• Bahr TM, et al. Ferritin in serum and urine: a pilot study. Blood Cells Mol Dis. 2019;76:59­­­­–62.
• Natali R, et al. Evaluation of a new venous catheter blood draw device and its impact on specimen hemolysis rates. Pract Lab Med. 2018;10:38–43.
• Gupta S, et al. Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget. 2018;9(11):9907–24.